Ghassan Bidaoui, Han Feng, Chanho Lim, Nour Chouman, Ala Assaf, Mayana Bsoul, Hadi Younes, Christian Massad, Yishi Jia, Yingshou Liu, Mario Mekhael, Charbel Noujaim, Eoin Donnellan, Omar Kreidieh, Amitabh C Pandey, Swati Rao, Nassir F Marrouche
{"title":"Atrial Arrhythmia Burden (SMURDEN) After Ablation of AF Is Associated With Improvement in Quality of Life.","authors":"Ghassan Bidaoui, Han Feng, Chanho Lim, Nour Chouman, Ala Assaf, Mayana Bsoul, Hadi Younes, Christian Massad, Yishi Jia, Yingshou Liu, Mario Mekhael, Charbel Noujaim, Eoin Donnellan, Omar Kreidieh, Amitabh C Pandey, Swati Rao, Nassir F Marrouche","doi":"10.1016/j.jacep.2025.07.011","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Among patients with persistent atrial fibrillation (AF), magnetic resonance imaging (MRI)-guided fibrosis ablation did not reduce arrhythmia recurrence compared with pulmonary vein isolation (PVI) alone.</p><p><strong>Objectives: </strong>The aim of this study was to assess the determinants of symptom and quality of life (QoL) change after PVI with or without MRI-guided ablation.</p><p><strong>Methods: </strong>This prespecified DECAAF II (Efficacy of Delayed Enhancement-MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation of Atrial Fibrillation) trial analysis included patients with persistent AF who had symptom severity scores before and after ablation. Patients were provided with a smartphone-based electrocardiography device for single-lead AF burden (SMURDEN) assessment. Participants completed the Atrial Fibrillation Symptom Severity (AFSS) and Short-Form 36 (SF-36) surveys at baseline, 3 months, and 12 months postablation. Symptom and QoL improvement determinants were explored through univariable and multivariable linear models.</p><p><strong>Results: </strong>Surveys from 750 patients were analyzed, revealing balanced baseline AFSS and SF-36 scores between the treatment arms (AFSS symptom score: mean ± SD = 12.3 ± 8.2 for PVI and 12.0 ± 8.0 for MRI-guided fibrosis ablation; P = 0.670). Symptoms improved in both arms (AFSS symptom score: 6.8 ± 0.5 for PVI and 7.3 ± 0.5 for MRI-guided fibrosis ablation; P = 0.114). Patients without AF recurrence exhibited greater improvement in most of the SF-36 subcategories and AFSS subcategories (P < 0.05). SMURDEN showed a correlation with QoL improvement and was the only predictor of no improvement or symptom worsening (R = 0.31; P < 0.001).</p><p><strong>Conclusions: </strong>Patients who experienced AF recurrence reported diminished symptom and QoL improvements. SMURDEN emerged as the most significant predictor of symptom improvement and was the only independent factor associated with a lack of improvement or worsening of symptoms.</p>","PeriodicalId":14573,"journal":{"name":"JACC. Clinical electrophysiology","volume":" ","pages":""},"PeriodicalIF":7.7000,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC. Clinical electrophysiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jacep.2025.07.011","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Among patients with persistent atrial fibrillation (AF), magnetic resonance imaging (MRI)-guided fibrosis ablation did not reduce arrhythmia recurrence compared with pulmonary vein isolation (PVI) alone.
Objectives: The aim of this study was to assess the determinants of symptom and quality of life (QoL) change after PVI with or without MRI-guided ablation.
Methods: This prespecified DECAAF II (Efficacy of Delayed Enhancement-MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation of Atrial Fibrillation) trial analysis included patients with persistent AF who had symptom severity scores before and after ablation. Patients were provided with a smartphone-based electrocardiography device for single-lead AF burden (SMURDEN) assessment. Participants completed the Atrial Fibrillation Symptom Severity (AFSS) and Short-Form 36 (SF-36) surveys at baseline, 3 months, and 12 months postablation. Symptom and QoL improvement determinants were explored through univariable and multivariable linear models.
Results: Surveys from 750 patients were analyzed, revealing balanced baseline AFSS and SF-36 scores between the treatment arms (AFSS symptom score: mean ± SD = 12.3 ± 8.2 for PVI and 12.0 ± 8.0 for MRI-guided fibrosis ablation; P = 0.670). Symptoms improved in both arms (AFSS symptom score: 6.8 ± 0.5 for PVI and 7.3 ± 0.5 for MRI-guided fibrosis ablation; P = 0.114). Patients without AF recurrence exhibited greater improvement in most of the SF-36 subcategories and AFSS subcategories (P < 0.05). SMURDEN showed a correlation with QoL improvement and was the only predictor of no improvement or symptom worsening (R = 0.31; P < 0.001).
Conclusions: Patients who experienced AF recurrence reported diminished symptom and QoL improvements. SMURDEN emerged as the most significant predictor of symptom improvement and was the only independent factor associated with a lack of improvement or worsening of symptoms.
期刊介绍：
JACC: Clinical Electrophysiology is one of a family of specialist journals launched by the renowned Journal of the American College of Cardiology (JACC). It encompasses all aspects of the epidemiology, pathogenesis, diagnosis and treatment of cardiac arrhythmias. Submissions of original research and state-of-the-art reviews from cardiology, cardiovascular surgery, neurology, outcomes research, and related fields are encouraged. Experimental and preclinical work that directly relates to diagnostic or therapeutic interventions are also encouraged. In general, case reports will not be considered for publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
